Cutaneous adverse effects of biologic medications

Selena R Pasadyn; Daniel Knabel; Anthony P Fernandez; Christine B Warren

doi:10.3949/ccjm.87a.19119

Cutaneous adverse effects of biologic medications

Cleve Clin J Med. 2020 May;87(5):288-299. doi: 10.3949/ccjm.87a.19119.

Authors

Selena R Pasadyn¹, Daniel Knabel², Anthony P Fernandez³, Christine B Warren⁴

Affiliations

¹ Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
² Department of Pathology and Department of Dermatology, Cleveland Clinic.
³ Co-Medical Director of Continuing Medical Education; W.D. Steck Chair of Clinical Dermatology; Director of Medical and Inpatient Dermatology; Departments of Dermatology and Pathology, Cleveland Clinic; Assistant Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
⁴ Department of Dermatology, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH warrenc@ccf.org.

PMID: 32357984
DOI: 10.3949/ccjm.87a.19119

Abstract

Biologic therapies have become widely used but often cause cutaneous adverse effects. The authors discuss the cutaneous adverse effects of tumor necrosis factor (TNF) alpha inhibitors, epidermal growth factor receptor (EGFR) inhibitors, small-molecule tyrosine kinase inhibitors (TKIs), and cell surface-targeted monoclonal antibodies, including how to manage these reactions and when to refer to a dermatologist.

Publication types

Review

MeSH terms

Biological Products* / adverse effects
Biological Products* / classification
Biological Products* / therapeutic use
Drug-Related Side Effects and Adverse Reactions* / diagnosis
Drug-Related Side Effects and Adverse Reactions* / etiology
Humans
Patient Care Management / methods*
Skin Diseases* / chemically induced
Skin Diseases* / diagnosis
Skin Diseases* / therapy

Substances

Biological Products